Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756031 | PMC |
| http://dx.doi.org/10.1038/s41375-019-0418-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial.
Oncoimmunology
November 2020
State Key Laboratory of Pharmaceutical Biotechnology, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, School of Life Science, Nanjing University, Nanjing, China.
Expressed by cancer stem cells of various epithelial cell origins and hepatocellular carcinoma (HCC), CD133 is an attractive therapeutic target for HCC. The marker CD133 is highly expressed in endothelial progenitor cells (EPC). EPCs circulate in increased numbers in the peripheral blood of patients with highly vascularized HCC and contribute to angiogenesis and neovascularization.
View Article and Find Full Text PDFCD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity.
Leukemia
August 2019
Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial.
Oncoimmunology
May 2018
Department of Molecular & Immunology, Chinese PLA General Hospital, Beijing, China.
Expressed by cancer stem cells of various epithelial cell origins, CD133 is an attractive therapeutic target for cancers. Autologous chimeric antigen receptor-modified T-cell directed CD133 (CART-133) was first tested in this trial. The anti-tumor specificity and the postulated toxicities of CART-133 were first assessed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!